Financial Disclosures Advisory Boards sanofi-aventis Merck Novo-Nordisk Grants sanofi-aventis
1 Aventis Pharma. 2 Prescription drugs Aventis Pharma Vaccines Aventis Pasteur Therapeutic proteins...
-
Upload
ezra-butler -
Category
Documents
-
view
215 -
download
0
Transcript of 1 Aventis Pharma. 2 Prescription drugs Aventis Pharma Vaccines Aventis Pasteur Therapeutic proteins...
1
Aventis Pharma
2
Aventis Pharma
Aventis Pharma
Prescription drugsAventis Pharma
VaccinesAventis Pasteur
Therapeutic proteinsAventis Behring
DiagnosticsDade Behring
3
Key Figures
•92, 500 employees – 80% in Pharma•16 Bn€ Pharma sales – 5th in top 10•Strong & growing US presence with >35% sales•19,000 member sales force •16.8% R&D expenditure; 6500 scientists &
technicians worldwide•15% of R&D expenditure dedicated to alliances;
about 50 major biotech collaborations; about 250 academic collaborations
4
Drug Innovation & Approval (R&D)Disease Groups supported by powerful technology
platforms
Gene Therapy*
-CV- Metabolic Diseases, - Osteoarthritis, Thrombosis
US
FRANCEGERMANY
JAPAN
Global and US Drug Devt Ctr
- Immunology platform - Respiratory diseases - RA - CNS
European Drug Devt Ctr
Asian Drug Devt Ctr
- Oncology, - Infectious Diseases - Neurodegenerative Diseases, (Parkinson & Alzheimer),
• ~6500 scientists & technicians worldwide
5
Drug Innovation & Approval in France
5 km
CDG Airport
ESSONNE
VAL DE MARNE
HAUTS DE SEINE
PARIS
SEINE ST DENIS
Romainville
Vitry-Alfortville
Croix de Berny
Evry
• Paris Research Centre• European Drug Devt Centre
• ~2800 scientists & technicians
6
New drug discovery technologies
Candidate Identification
LeadIdentification
TargetSelection
PreclinicalCandidate
Identification PhI / IIaPhIIb PhIII Regulatory
Review
Functional Genomics Technologies DNA chipsProteomics, cellular & animal models..
Lead Identification Technologies MedChem, ChemBiol, Structural Genomics and Biology…. Technologies for Exploratory
Development eADMET, TGX, PGX, Biomarkers….
Technologies for Global
Rapid submissions e-submissions…..
Integrated Data and Knowledge Management
7
Integration of Genomics Technologies &Disease Biology Platforms
GenomicsTechnologyPlatforms
Aventis Genomics Centers
DiseaseBiology
Platforms
Metabolism OncologyCNS / ND
Cardiovascular Rheumatoid
Arthritis Osteoarthritis - DJD Respiratory Diseases Anti-
Infectives Immunology
platform
Exte
rnal C
ollab
ora
tion
s &
N
etw
ork
s
Exte
rnal C
ollab
ora
tion
s &
N
etw
ork
s
Targets relevant to disease
8
Key Challenges
•The post-human genome sequence race • functional genomics• proteomics• protein structure prediction • re-thinking chemical approaches• re-thinking clinical development
•Continuous integration of technologies (alliances and partnering), information and knowledge (knowledge networks)
•Availability of skilled work force (right skill-set and mind-set)
9
In partnership with the European Commission: 12 Marie Curie Industry
Host Fellowships for a 2 year period.
Post-doc Opportunities in Aventis Pharma, France
•Parkinson’s Disease Gene Targets (3 positions)
•Molecular Modeling and High Throughput Medicinal Chemistry (3 positions)
•From Protein-Protein Interactions (yeast 2H) to Lead Discovery Process (3positions)
•Cardiovascular Gene Therapy (1 position)
•Adenoviral Vector-based system for Functional Genomics (1 position)
•Bio-Informatics in Toxicogenomics (1 position)
Immediate Starting Date
10
In partnership with the European Commission
Post-doc Opportunities in Aventis Pharma, France
The position are open to members of the E.C. or resident of associated countries for more than 5 years.
The age limit at the time of selection is 35 years old. Austria, Belgium, Bulgaria, Czech republic, Denmark, Estonia, Finland, Germany
Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Liechtenstein
Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Republic of Cyprus, Romania
Slovakia, Slovenia, Sweden, Spain, United Kingdom
However French citizens are ineligible as well as those who have been resident in France for more than 12 out of the last 24 months.
11
Coming soon
9 post-doctoral positions
Post-doc Opportunities in Aventis Pharma, France
•Kinases in Oncology and Neurodegenerative diseases•Gene Transfer in Angiogenesis
•Genomic Studies for the glial-neuronal interactions
•Statistics for Pharmacogenetics
12
Post-doc Opportunities in Aventis Pharma, France
• 250 KF/year (38KEuros/year)• Social security included• 26 + 12 days holiday
• Project Team • Networking• Publications/patents
• Confidentiality
13
Come and join us on the Aventis stand to learn more about our post-doctoral opportunities !